Aileen Jean Fiona King

Aileen Jean Fiona King

Auto-generated profile, based on publicly available information

Aileen Jean Fiona King

Department of Diabetes, School of Cardiovascular and Metabolic Medicine & Sciences King's College London London UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2012 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
AKAileen Jf King
Aileen Jf King
Diabetes is a disease characterized by a relative or absolute lack of insulin, leading to hyperglycaemia. There are two main types of diabetes: type 1 diabetes and type 2 diabetes. Type 1 diabetes is due to an autoimmune destruction of the insulin‐producing pancreatic beta cells, and type 2 diabetes is caused by insulin resistance coupled by a failure of the beta cell to compensate. Animal models for type 1 diabetes range from animals with spontaneously developing autoimmune diabetes to chemical ablation of the pancreatic beta cells. Type 2 diabetes is modelled in both obese and non‐obese animal models with varying degrees of insulin resistance and beta cell failure. This review outlines some of the models currently used in diabetes research. In addition, the use of transgenic and knock‐out mouse models is discussed. Ideally, more than one animal model should be used to represent the diversity seen in human diabetic patients.LINKED ARTICLES: Animal ModelsThis paper is the latest in a series of publications on the use of animal models in pharmacology research. Readers might be interested in the previous papers.Robinson V (2009). Less is more: reducing the reliance on animal models for nausea and vomiting research.Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PLR (2009). Opportunities for the replacement of animals in the study of nausea and vomiting.Giacomotto J and Ségalat L (2010). High‐throughput screening and small animal models, where are we?McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines.Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). The ARRIVE guidelines.Emerson M (2010). Refinement, reduction and replacement approaches to in vivo cardiovascular research.Berge O‐G (2011). Predictive validity of behavioural animal models for chronic pain.Vickers SP, Jackson HC and Cheetham SC (2011). The utility of animal models to evaluate novel anti‐obesity agents.Percie du Sert N, Holmes AM, Wallis R, Andrews PLR (2012). Predicting the emetic liability of novel chemical entities: a comparative study.The complete series including future publications, as they occur, can be found at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476‐5381/homepage/animal_models.htm.

1 February 2009 in Diabetes
Verified
Journal Article
Open access
AHAstrid C. Hauge-Evans
Astrid C. Hauge-Evans
AKAileen J. King
Aileen J. King
DCDanielle Carmignac
Danielle Carmignac
CRCarolyn C. Richardson
Carolyn C. Richardson
IRIain C.A.F. Robinson
Iain C.A.F. Robinson
PJPeter Martin Jones
Peter Martin Jones
OBJECTIVE— Somatostatin (SST) is secreted by islet δ-cells and by extraislet neuroendocrine cells. SST receptors have been identified on α- and β-cells, and exogenous SST inhibits insulin and glucagon secretion, consistent with a role for SST in regulating α- and β-cell function. However, the specific intraislet function of δ-cell SST remains uncertain. We have used Sst−/− mice to investigate the role of δ-cell SST in the regulation of insulin and glucagon secretion in vitro and in vivo. RESEARCH DESIGN AND METHODS— Islet morphology was assessed by histological analysis. Hormone levels were measured by radioimmunoassay in control and Sst−/− mice in vivo and from isolated islets in vitro. RESULTS— Islet size and organization did not differ between Sst−/− and control islets, nor did islet glucagon or insulin content. Sst−/− mice showed enhanced insulin and glucagon secretory responses in vivo. In vitro stimulus-induced insulin and glucagon secretion was enhanced from perifused Sst−/− islets compared with control islets and was inhibited by exogenous SST in Sst−/− but not control islets. No difference in the switch-off rate of glucose-stimulated insulin secretion was observed between genotypes, but the cholinergic agonist carbamylcholine enhanced glucose-induced insulin secretion to a lesser extent in Sst−/− islets compared with controls. Glucose suppressed glucagon secretion from control but not Sst−/− islets. CONCLUSIONS— We suggest that δ-cell SST exerts a tonic inhibitory influence on insulin and glucagon secretion, which may facilitate the islet response to cholinergic activation. In addition, δ-cell SST is implicated in the nutrient-induced suppression of glucagon secretion.

23 July 2014 in Journal of Endocrinology
Verified
Journal Article
Closed access
JBJames E Bowe
James E Bowe
ZFZara J Franklin
Zara J Franklin
AHAstrid C Hauge-Evans
Astrid C Hauge-Evans
AKAileen J King
Aileen J King
SPShanta J. Jean Persaud
Shanta J. Jean Persaud
PJPeter Martin Jones
Peter Martin Jones
The pathophysiology of diabetes as a disease is characterised by an inability to maintain normal glucose homeostasis. In type 1 diabetes, this is due to autoimmune destruction of the pancreatic β-cells and subsequent lack of insulin production, and in type 2 diabetes it is due to a combination of both insulin resistance and an inability of the β-cells to compensate adequately with increased insulin release. Animal models, in particular genetically modified mice, are increasingly being used to elucidate the mechanisms underlying both type 1 and type 2 diabetes, and as such the ability to study glucose homeostasisin vivohas become an essential tool. Several techniques exist for measuring different aspects of glucose tolerance and each of these methods has distinct advantages and disadvantages. Thus the appropriate methodology may vary from study to study depending on the desired end-points, the animal model, and other practical considerations. This review outlines the most commonly used techniques for assessing glucose tolerance in rodents and details the factors that should be taken into account in their use. Representative scenarios illustrating some of the practical considerations of designingin vivoexperiments for the measurement of glucose homeostasis are also discussed.

1 January 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
AKAileen King
Aileen King
JBJames Bowe
James Bowe

26 January 2011 in Diabetologia
Verified
Journal Article
Closed access
PDF file
CRC. L. Rackham
C. L. Rackham
PCP. C. Chagastelles
P. C. Chagastelles
NNN. B. Nardi
N. B. Nardi
AHA. C. Hauge-Evans
A. C. Hauge-Evans
PJPeter Martin Jones
Peter Martin Jones
AKA. J. F. King
A. J. F. King